title: Comparison of primary octreotide-lar and surgical treatment in newly diagnosed patients with acromegaly.
abstract: OBJECTIVE
  The primary aim of the study was to compare the efficacy of Oct-LAR and surgery in terms of controlling IGF-1 and GH levels and tumour volumes. The second aim was to compare two primary treatment modalities in terms of side effects such as pituitary insufficiency, cholelithiasis, metabolic parameters and the effect on quality of life (QoL).
  
  
  METHODS
  The study was a randomized, prospective study.
  
  
  METHODS
  The 22 patients were consecutively randomized to Oct-LAR and surgical treatment groups.
  
  
  RESULTS
  Baseline serum IGF-1 level, tumour volume and GH levels were comparable in the Oct-LAR and surgery groups. No significant differences were detected between the Oct-LAR and the surgery groups in terms of IGF-1 and GH levels at the 3rd and 6th months, but at 12th month, preglucose GH was found to be lower in the surgical treatment group. IGF-1 control and complete biochemical response rates were found to be 27% and 64%, in the Oct-LAR and surgical treatment groups, respectively. The mean percentage of tumour volume reduction was found to be 26%, 30% and 31% in the Oct-LAR group vs 64%, 74% and 79% in the surgery group at the 3rd, 6th and 12th months, respectively.
  
  
  CONCLUSIONS
  Primary surgical treatment seems to be slightly more effective than Oct-LAR in terms of biochemical response and IGF-1 control, besides tumour volume reduction, in patients with acromegaly with noninvasive tumours. Oct-LAR is associated with more side effects such as cholelithiasis and glucose metabolism disorders and is more expensive.
authors.affiliation: Department of Endocrinology, Erciyes University Medical School, Kayseri, Turkey.
authors.forename: Z
authors.initials: Z
authors.lastname: Karaca
authors.forename: F
authors.initials: F
authors.lastname: Tanriverdi
authors.forename: G
authors.initials: G
authors.lastname: Elbuken
authors.forename: I
authors.initials: I
authors.lastname: Cakir
authors.forename: H
authors.initials: H
authors.lastname: Donmez
authors.forename: A
authors.initials: A
authors.lastname: Selcuklu
authors.forename: A C
authors.initials: AC
authors.lastname: Durak
authors.forename: H S
authors.initials: HS
authors.lastname: Dokmetas
authors.forename: R
authors.initials: R
authors.lastname: Colak
authors.forename: K
authors.initials: K
authors.lastname: Unluhizarci
authors.forename: F
authors.initials: F
authors.lastname: Kelestimur
mesh_terms: D000172:Acromegaly / Q000097:blood / Q000188:drug therapy* / Q000601:surgery*; D000328:Adult; D000368:Aged; D002769:Cholelithiasis / Q000097:blood / Q000175:diagnosis; D005260:Female; D006801:Humans; D007018:Hypopituitarism / Q000097:blood / Q000175:diagnosis; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000627:therapeutic use*; D011446:Prospective Studies; D011788:Quality of Life
chemical_list: D015282:Octreotide